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Abstract
Due to lower female incidence, estimates of exogenous and endogenous hormonal factors in head and neck cancers (HNCs, comprising cancers of the oral
cavity, oropharynx, hypopharynx, and larynx) among women have been inconsistent and unable to account for key HNC risk factors. We pooled data from
11 studies from Europe, North America, and Japan. Analysis included 1572
HNC female cases and 4343 controls. Pooled odds ratios (ORs) estimates and
their 95% confidence intervals (CIs) were calculated using multivariate logistic
regression models adjusting for tobacco smoking and alcohol drinking. Lower
risk was observed in women who used hormone replacement therapy (HRT)
(OR = 0.58; 95% CI: 0.34–0.77). Pregnancy (OR = 0.61; 95% CI: 0.42–0.90)
and giving birth (OR = 0.59; 95% CI: 0.38–0.90) at <35 years of age were
inversely associated with HNCs. An inverse association with HNC was observed
with age at start of HRT use (OR = 0.59; 95% CI: 0.39–0.90) for each additional
10 years and with duration of use (OR = 0.87; 95% CI: 0.76–0.99 for every
3 years). Exogenous female hormone use is associated with a nearly twofold
risk reduction in female HNCs. The lower female HNC incidence may, in part,
be explained by endogenous and exogenous estrogen exposures.

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
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Introduction
The male-
to-
female incidence ratio of head and neck
cancers (HNCs) of the oral cavity, pharynx, oropharynx,
hypopharynx, and larynx ranges in the order of 3 to 5
to 1 [1]. Differences in tobacco smoking, alcohol drinking, and human papilloma virus (HPV) infection do not
fully explain this sex incidence ratio [2]. Indeed, for
laryngeal cancer, the male-to-female incidence ratio is the
highest among non-sex-related neoplasms at 11:1 [1]. HNC
incidence rates are increasing among females [3, 4] although
female HNCs are understudied.
The paucity of literature on female HNCs is due to
low female case numbers available at each individual
institution, low female HNC incidence, and a lack of
standardized reproductive or hormone use data collection
on HNC patients in general [5]. However, estrogen hormone receptors have been shown to be functional [6] in
HNC cell lines, expressed depending on hormone ligand
stimulation [7], and, recently, correlated with HNC survival status [8]. However, the role of hormones in head
and neck carcinogenesis in a human model remains unclear.
Epidemiological studies support a favorable role of exogenous and endogenous female hormones on HNCs [3,
5, 9]. However, these studies included <200 cases and
lacked statistical power to concurrently adjust for both
tobacco smoking and alcohol drinking confounders.
To clarify the role of hormonal factors in female HNC
risk, we pooled primary data from 11 HNC case–control
studies in the International Head and Neck Cancer
Epidemiology (INHANCE) consortium. This study aimed
to evaluate the role of female exogenous and endogenous
hormones on female HNC risk and to determine the
interaction between female hormones and known risk
factors with HNC risk.

Methods
Study population
We pooled 1572 female incident HNC cases and 4343
controls from 11 INHANCE studies (http://www.inhance.

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

utah.edu/) [10]. Controls were frequency-matched by age,
sex, and race/ethnicity. Controls obtained via random-
digit-dialing (Iowa and US multicenter studies) or matchedbased on residence (Milan (2006–2009)) included 1288
(25%) participants (Table S1). Case and control participation rates were greater than 94%, aside from Iowa, US
multicenter, and Buffalo studies, which had participation
percent rates over 87%, 75%, and 75%, respectively [11].
Incident HNC cases were defined by the following codes
of the World Health Organization (WHO) International
Classification of Disease (ICD-O2 Version 2 [12], ICD-9
[13], or ICD-10 [14]) and included: oral cavity (n = 558),
(C00.3-
C00.9, C02.0-
C02.3, C03.0, C03.1, C03.9, C04.0,
C04.1, C04.8-C05.0, C06.0-
C06.2, C06.8, C06.9); oropharynx (n = 339), (C01.9, C02.4, C05.1, C05.2, C09.0,
C09.1, C09.8, C09.9, C10.0-
C10.4, C10.8, C10.9);
hypopharynx (n = 99) (C12.9, C13.0-13.2, C13.8, C13.9);
and larynx (n = 212) (C32.0-
C32.3, C32.8, C32.9), as
well as pharynx not otherwise specified (n = 302) and
overlapping HN sites (n = 62). Due to the specific HPV-
driven etiology of oropharyngeal cancers [15], they were
analyzed separately.

Exposure variables
Data were collected by trained interviewers using structured questionnaires including menstrual and reproductive
information, lifelong use of oral contraceptives (OC) and
hormone replacement therapy (HRT), age at menopause
and menarche, socio-
demographics, and smoking and
drinking habits. HRT therapy was defined as hormone
therapy for menopausal symptoms. Written informed
consent was obtained from all study subjects; each institutional review board approved investigations.
Questionnaire data were collected from each study to
assess question wording and data comparability, for data
harmonization. Reliability for HRT therapy and OC use
were over 90% and 93%, respectively; for parity and age
at menopause, 94% and 66%, respectively [16–18]. Study
subjects had a mean age±standard deviation(SD) of
59.0 ± 0.17 years, within the upper range of the world
menopausal age average [19]. Categorical age cut-offs at
1999
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Table 1. Associations between exogenous and endogenous hormone-related factors with the risk of head and neck cancer and by subsite in
INHANCE Consortium.
Overall Head and Neck Cancers

Oral Cavity

Cases/Controls

OR (95% CI)

Cases/Controls

OR (95% CI)

Cases/Controls

OR (95% CI)

1.0 (Ref.)
0.58 (0.34–0.77)

139/791
266/1,351

1.0 (Ref.)
0.56 (0.32–0.97)

134/791
325/1,351

1.0 (Ref.)
0.49 (0.31–0.77)

1.0 (ref.)
1.59 (0.47–5.35)

41/521
21/98

60/521
29/98

1.0 (ref.)
0.82 (0.08–8.77)

0.93 (0.27–3.18)

16/112

1.0 (ref.)
1.05
(0.10–10.52)
0.64 (0.06–7.34)

25/112

2.17
(0.23–20.19)
0.18

Exogenous Hormone factors
Ever used HRT1
Never
370/791
Ever
626/1,351
Age at first HRT use (years)
Never
122/521
<42
51/98
42+

42/112

Ptrend
Ever used OC2
Never
349/1,373
Ever
88/335
Age at first OC use (years)
Never
348/1,372
<31
61/182
31+
30/180
Ptrend
Endogenous hormone factors
Ever given birth
No
161/360
Yes
400/1612
Age at first pregnancy (years)
Never
119/248
<35
555/1980
35+
17/47
Ptrend
Age at first birth (years)
Never
112/232
<35
544/1,925
35+
17/47
Ptrend
Breastfeeding
No
391/1,197
Yes
125/361
Menarche age
14 years+
322/1024
<14 years
359/1307
Menopause cause
Pre-and peri
115/510
menopause
Natural
513/1746
Surgical
124/423
Menopause age
Never
70/416
<52 years
476/1494
52+ years
172/701
Ptrend

0.32

Oropharynx

0.34

1.0 (Ref.)
0.59 (0.40–0.86)

110/1,373
31/335

1.0 (Ref.)
0.64 (0.36–1.17)

150/1,373
33/335

1.0 (Ref.)
0.55 (0.29–1.07)

1.0 (Ref.)
0.83 (0.52–1.34)
0.37 (0.22–0.63)
<0.001

109/1,372
18/182
14/180

1.0 (Ref.)
0.73 (0.35–1.54)
0.55 (0.26–1.18)
0.12

150/1,372
25/182
10/180

1.0 (Ref.)
0.86 (0.38–1.95)
0.31 (0.12–0.79)
0.02

1.0 (Ref.)
0.70 (0.52, 0.95)

60/360
136/1,612

1.0 (Ref.)
0.74 (0.47–1.16)

74/360
152/1612

1.0 (Ref.)
0.61 (0.36–1.02)

1.0 (Ref.)
0.61 (0.42–0.90)
0.82 (0.39–1.71)
0.09

47/248
187/1,980
5/47

1.0 (Ref.)
0.55 (0.30–0.98)
0.65 (0.21–2.08)
0.11

54/248
261/1,980
8/47

1.0 (Ref.)
0.48 (0.25–0.93)
0.43 (0.09–2.13)
0.04

1.0 (Ref.)
0.59 (0.38–0.90)
0.78 (0.37–1.65)
0.03

42/232
182/1,925
5/47

1.0 (Ref.)
0.44 (0.22–0.90)
0.50 (0.14–1.61)
0.03

53/232
147/1925
8/47

1.0 (Ref.)
0.48 (0.24–0.95)
0.39 (0.08–1.94)
0.04

1.0 (Ref.)
0.97 (0.67–1.43)

127/1197
44/361

1.0 (Ref.)
1.02 (0.55–1.88)

209/1,197
54/361

1.0 (Ref.)
0.98 (0.50–1.96)

1.0 (Ref.)
0.89 (0.73–1.10)

110/1024
111/1307

1.0 (Ref.)
0.81 (0.58–1.12)

88/1024
95/1307

1.0 (Ref.)
0.74 (0.50–1.11)

1.0 (Ref.)

41/510

1.0 (Ref.)

56/510

1.0 (Ref.)

1.79 (1.16–2.77)
1.62 (1.02–2.56)

184/1,746
46/423

1.44 (0.72–2.87)
1.37 (0.67–2.81)

231/1746
52/423

1.98 (0.92–4.28)
1.89 (0.92–3.88)

1.0 (Ref.)
1.69 (1.06–2.71)
1.54 (0.93–2.57)
0.33

22/416
168/1494
63/701

1.0 (Ref.)
0.94 (0.44–2.01)
0.86 (0.38–1.92)
0.56

41/416
212/1,494
78/701

1.0 (Ref.)
2.52 (1.02–6.27)
1.88 (0.68–5.24)
0.95

Models adjusted for study (and center for multicenter studies), age (<40, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75 + years), education
level (≤high school, > high school), amount of alcohol drinking (nondrinker, 0.1–0.9, 1.0–2.9, 3.0–4.9, and 5.0+ drinks/day), body mass index (normal
weight, underweight, overweight, and obese), and cumulative tobacco smoking (never smoker, smoked 0–10.0, 10.1–20.0, 20.1–30.0, 30.1–40.0,
40.1–50.0, 50.0+ pack-years).
1HRT, hormone replacement therapy.
2OC, oral contraceptives; OR: Odds ratios.

2000
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menopause and menarche were chosen based on the
pooled data median. First birth and pregnancy 35+ years
was chosen based on the clinical definition of advanced
maternal age, hormonal changes, and cancer risk [20,
21]. Given the well-established relationship between body
mass index (BMI) and female hormones, we also analyzed
the association between BMI with HNCs [22, 23]. In
most studies (both Milan studies, Aviano, Italy Multicenter,
Switzerland, and US Multicenter) BMI was ascertained
at enrollment, while in others (Buffalo, Iowa, Rome, and
both Japan studies) BMI was ascertained 2–5 years earlier.
The Pearson correlations were over 0.88, and BMI odds
ratios (ORs) for HNC were similar between all studies.
Alcohol consumption was calculated in standardized
drinks/day [24].

Statistical analyses
Associations between hormone factors and HNC were
assessed by OR and corresponding 95% confidence intervals
(CIs) using multivariate logistic regression models. To
determine summary associations, study-specific estimates
were included in a multivariate two-stage random-effects
logistic regression model [25], allowing for study heterogeneity. Variables with the largest number of data by
study are displayed using both random-
effects models.
Pooled odds ratios were also estimated with a fixed-effects
logistic regression model for each hormone variable, adjusting for age, education, study, BMI, tobacco smoking, and
alcohol, as described previously [3, 26, 27].
For stratified analyses, separate multivariable models
were run for never and former/current smokers to minimize the possible confounding of former smokers. The
same method was applied to alcohol drinking. BMI categories were separated as: underweight-<18.5 kg/m2,
normal-18.5–24.9 kg/m2, overweight-25–29.9 kg/m2, and
obese- ≥30 kg/m2. We also included interaction terms to
determine modifying effects between hormone variables
and smoking and drinking. A Student’s t-test was used
to determine whether means for months of exogenous
hormone differed between cases and controls. All analyses
were performed using Stata version 14.0 (StataCorp.,
College Station, Texas) and P < 0.05 was considered
significant.

Results
The distributions of cases and controls by selected characteristics are reported in Table S2. A total of 546 HNC
cases (36.6%) were nondrinkers versus 1882 (47.2%)
controls who were nondrinkers. Nonsmokers included
506 (33.5%) cases and 2536 (63.7%) controls. A high
school education or more was inversely associated with

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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HNCs (OR = 0.77; 95% CI: 0.65–0.92) with a dose–
response effect (Ptrend based on five categories<0.001). This
association remained after adjustment for hormonal factors; effect modification with hormone variables was
P = 0.76. Mean BMI for cases was 23.1 kg/m2 ± 0.12
standard deviation (SD) versus controls 24.5 kg/m2 ± 0.13
SD; P < 0.001. No association was observed for HNCs
by BMI category (Table S3); effect modification for BMI
with all hormone variables were all P > 0.05; data not
shown.

Exogenous hormone use
Inverse associations were observed across all HNC and
cancer sites for both HRT and OC use (Table 1). Respective
ORs and 95% CIs between ever using HRT and HNC,
oral cavity cancer, and oropharyngeal cancer were 0.58
(0.34–0.77), 0.56 (0.32–0.97), and 0.49 (0.31–0.77), respectively. For OC use, a dose–response relationship with age
was observed, with inverse associations for those who
started at 31+ years old (OR = 0.37, 95% CI: 0.22–0.63;
Ptrend < 0.001). When age at first OC use was treated as
a continuous variable, a similar inverse association was
observed: OR = 0.61; 95% CI: 0.47–0.82 for all HNCs
and oropharyngeal cancer (OR = 0.60; 95% CI: 0.39–0.92),
but not oral cavity cancer (OR = 0.67; 95% CI:
0.42–1.07).
Among women who used HRT, an inverse association
with HNC was OR = 0.59 (95% CI: 0.39–0.90) for each
additional 10 years of age at which HRT was started. For
every additional 3 years that HRT use continued, HNC
risk decreased by 13% (OR = 0.87; 95% CI: 0.76–0.99).
Only seven cases and 26 controls had ever used both
HRT and OC. There was no significant difference between
months of HRT use (25.6 ± 60.3 SD vs. 23.5 ± 63.6 SD;
P = 0.61) or months of OC use (10.4 ± 32.5 SD vs.
8.2 ± 28.5 SD; P = 0.16) between cases and controls,
respectively.

Endogenous hormones: reproductive and
menstrual variables
Giving birth was inversely associated with all HNCs. An
inverse relationship was observed for age at first pregnancy
and age at first birth <35 years versus never having been
pregnant or given birth for all HNCs, oral cancers, and
oropharyngeal cancers. The number of births was not
significantly associated with HNCs [Respective ORs and
95% CIs for HNC: 0.94 (0.88–1.01), oral cavity: 0.93
(0.83–1.04), and pharynx: 0.92 (0.83–1.02)] (data not
shown). There were no appreciable associations between
having had a miscarriage or abortion with HNCs, or with
subsites (data not shown).
2001
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Figure 1. Association between the use of HRT, oral contraceptives, and ever given birth with the risk of head and neck cancer by study in INHANCE
Consortium.

Menopause at <52 years old was associated with higher
risk of all HNCs. Menopause due to both natural and
surgical causes was associated with higher risk of HNCs
compared to pre-and peri-menopausal women. However,
when menopause type was adjusted for HRT use, associations attenuated for both naturally and surgically induced
menopause [(Natural menopause: OR = 1.46; 95% CI:
0.74–2.85; n = 98 HRT use/n = 145 no HRT use) and
Surgical menopause: OR = 1.17; 95% CI: 0.58–2.37;
(n = 25 HRT use/n = 45 no HRT use)]. No association
was observed between age at menarche with all HNCs
or subsites, both in continuous scale (data not shown)
and categorical scale (<14 vs. 14+ years of age). Similarly,
menstrual cycle duration (OR = 1.04; 95% CI: 0.94–1.14)
and menstrual period duration (OR = 0.96; 95% CI:
0.87–1.05) were not associated with HNCs (data not
shown).
Between-study heterogeneity was not detected. Inverse
associations were observed between ever using HRT and
all HNCs (Fig. 1) as well as oral cavity and oropharyngeal
cancers in random-effects models [Respective pooled ORs
and 95% CIs: 0.58 (0.31–0.84); 0.49 (0.29–0.75)]. Similar
to fixed-effects models, ever OC use was inversely associated with overall HNCs [Respective pooled ORs and 95%
CIs: 0.55 (0.28–0.83)] but not for oropharyngeal cancers:
0.46 (0.06–0.98). Ever giving birth was inversely associated
with all HNCs as well as both oral cavity and oropharynx
cancer subsites [Respective pooled ORs and 95% CIs: 0.54
(0.34–0.75); 0.25 (0.10–0.41); 0.54 (0.21–0.82)].
2002

HNC risk and hormones, by smoking and
drinking
HRT use
Ever using HRT remained inversely associated with all
HNCs, oral cavity, and oropharyngeal cancers in ever-
smokers only (Table 2). An interaction between smoking
status and HRT was observed for oropharyngeal cancer.
Interactions for HRT and alcohol drinking were observed
for HNCs and oral cavity cancers (Pinteraction = 0.01 and
0.002, respectively).
OC use
The association between oropharyngeal cancer and ever
OC use was inversely associated for ever-
smokers, but
not observed for never-smokers. No interaction between
smoking and OC use was observed for HNC overall.
However, an inverse association was observed between
OC use and all HNCs in stratified analyses for ever-
drinkers, with significant interaction (Pinteraction=0.02), but
not for never-drinkers.
Ever given birth
No interactions were observed between giving birth and
HNCs when stratified for alcohol drinking. An interaction
was observed for HNCs and smoking (Pinteraction = 0.02).
The risk of oropharyngeal cancer was lower for

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Table 2. Risk of head and neck cancer overall and for subsites in tobacco smokers and alcohol drinkers within strata of endogenous and exogenous
hormones variables, INHANCE Consortium.
Overall head and neck
Cases
–
(E/E )

Controls
–
(E/E )

Ever used HRT (ever vs. never)
Alcohol drinking status
Never 133/191 415/638
Ever

219/427 330/685

Tobacco smoking status
Never 98/199 492/864
Ever

267/426 283/479

Ever used OC (ever vs. never)
Alcohol drinking status
Never 21/75
97/532
Ever

63/273

226/798

Tobacco smoking status
Never 24/98
184/991
Ever

63/249

147/378

Ever given birth (ever vs. never)
Alcohol drinking status
Never 103/41 565/160
Ever

287/117 990/191

Oral cavity
OR (95% CI)

Pinteract

Oropharynx

Cases
–
(E/E )

Controls
–
(E/E )

OR (95% CI) Pinteract

44/95

415/638

0.44
(0.15–1.26)
0.70
(0.36–1.37)

0.01
0.50
(0.25–1.00)
0.61
(0.36–1.05)
0.06
1.04
(0.63–1.73)
0.58
(0.39–0.85)

97/161 283/479

0.02
97/532

23/76

226/798

8/41

184/991

23/68

147/378

42/15

565/160

92/45

990/191

0.53
(0.15–1.90)
0.65
(0.32–1.32)

415/638

42/127

330/685

0.47
(0.15–1.48)
0.48
(0.29–0.80)

11/37

492/864

41/137

283/479

4/20

97/532

18/98

226/798

8/21

184/991

13/62

147/378

22/9

565/160

67/33

990/191

30/5

1,074/217 1.39
(0.46–4.20)
520/139
0.46
(0.25–0.88)

0.02
0.70
(0.25–2.02)
0.45
(0.27–0.75)
0.14
0.35
(0.07–1.88)
0.54
(0.26–1.10)
0.01
1.20
(0.43–3.38)
0.39
(0.17–0.91)

0.45

Tobacco smoking status
<0.001
Never 104/42 1074/217 0.80
42/15
(0.50–1.27)
Ever
278/111 520/139 0.68
89/43
(0.46–1.00)

0.79
(0.44–1.40)
0.78
(0.35–1.72)

0.08
0.85
(0.29–2.50)
0.68
(0.36–1.25)

0.12
1074/217
520/139

0.81
(0.42–1.56)
0.77
(0.42–1.43)

Pinteract

0.75

0.60
0.56
(0.22–1.45)
0.83
(0.37–1.82)

0.28
0.89
(0.61–1.30)
0.50
(0.29–0.84)

10/45

0.61
6/30

0.21
0.82
(0.46–1.47)
0.63
(0.39–1.01)

OR (95% CI)

0.31
41/104 492/864

0.74
(0.34–1.61)
0.53
(0.34–0.83)

Controls
–
(E/E )

0.002

92/167 330/685

0.49
(0.23–1.04)
0.50
(0.31–0.82)

Cases
–
(E/E )

0.06

59/39

Models adjusted for study (and center for multicenter studies), age (<40, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75+ years), education
level (≤high school, > high school), amount of alcohol drinking (nondrinker, 0.1–0.9, 1.0–2.9, 3.0–4.9, and 5.0+ drinks/day), body mass index (normal
weight, underweight, overweight, and obese), and cumulative tobacco smoking (never smoker, smoked 0–10.0, 10.1–20.0, 20.1–30.0, 30.1–40.0,
40.1–50.0, 50.0+ pack-years).
–
E, exposed; E , unexposed; HRT, hormone replacement therapy; OC, oral contraceptives; OR, Odds ratios.

ever-smokers who had given birth than for never-smokers.
Interactions between hormone variables and BMI for HNC
risk were: P = 0.15 for HRT use, P = 0.50 for OC use,
and P = 0.78 for ever given birth.

Discussion
This study accomplished an adequately powered investigation of major exogenous and endogenous hormone-related
variables on female total HNCs as well as oral cavity
cancers, and oropharyngeal cancer subsite risk by pooling
primary data from multiple studies. We confirmed an
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inverse relationship between multiple estrogen-
progesterone hormone factors and HNC risk among
females, an understudied population. Associations were
favorable for high-estrogen endogenous states, specifically
earlier first pregnancy and earlier menarche, and inconsistent for age at menopause which supports risk susceptibility at younger age of exposure. The relationship between
hormones factors and HNCs appears to be modified by
alcohol drinking and smoking status, consistent with known
biological mechanisms of these cancer risk factors on
female hormones. Considering our stratification for tobacco
and alcohol exposure still resulted in inverse associations
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for hormone variables among those with high cancer risk,
we interpret this to mean that the decrease in female
HNC risk could not be solely explained by tobacco or
alcohol alone.
Some studies on female HNCs suggested a favorable
effect of some hormone factors [28], while others found
null associations [28]. Accumulated, the evidence supports
a mixed causal effect of both sex (biological) and gender
(psycho-
sociological) differences on HNC [29, 30] with
a protective relationship with younger exposure age.
Biologically higher natural estrogen levels among women
have been proposed as an explanation for lower risk of
HNCs compared to men. As ~90% of HNCs are squamous cell carcinomas, this hypothesis is analogous with
findings among other upper-thoracic squamous cell carcinomas in women demonstrating a favorable associations
of female combination hormones for cancers of the oral
cavity and pharynx [3], and esophagus [31], including a
prospective study [32].Associations for hormone use with
esophageal squamous cell carcinoma were stronger than
for adenocarcinoma [31, 32]. For HNCs specifically, experimental in vitro and in vivo studies support a plausible
biological mechanism for hormone ligand action. Lukits
and colleagues [6] demonstrated evidence for estrogen
and progesterone receptors in 67 of human HNC surgical
samples. Colella et al.[33] found that hormone expression
patterns differ between malignant versus nonmalignant
oral mucosa tissue. The beta estrogen receptor (ERβ) in
particular, functions as a tumor suppressor by inhibiting
proliferation and driving cellular differentiation [34] and
ERβ positivity has been correlated with improved survival
of oropharyngeal cancer patients [8]. Moreover, the selective estrogen receptor modulator, tamoxifen, has been
shown to arrest G1 in HNC cell lines, sensitizing cancer
cells to chemotherapy-induced apoptosis [35, 36]. These
findings indicate that specific biological mechanisms exist
by which hormone levels can influence HNC phenotypes
when receptors are activated.
A second explanation for the inverse relationship between
estrogenic hormones on female HNCs is the influence of
estrogen on liver metabolism. CYP1B1, part of the
Cytochrome P450 enzyme superfamily, plays a key role
in sex hormone metabolism and homeostasis. Shatalova
et al.[37] found estrogen exposure of premalignant HNC
cells reduced CYP1B1 gene expression. Yoo et al. [38]
examined estrogen metabolites in 50:50 HNC case–controls
and found higher abnormal estrogen metabolism expression among cases (OR = 15.6;95% CI: 1.1–212.5). The
stratified hormone analyses for our study showed a stronger
inverse relationship among ever-drinkers. Given that consistent alcohol drinkers have altered liver metabolism and
higher estrogen levels, it is plausible that the combination
of exogenous estrogen level exposure and alcohol may
2004
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work in tandem to decrease HNC risk estimates and may
explain P values < 0.05 for interaction as well as an
inverse association for female ever-
drinkers (OR =
0.53[95% CI: 0.34–0.83]. This pattern was confirmed for
our study when we restricted analyses to heavy drinkers
(≥3.0 drinks per day) (OR for HRT use = 0.34; 95% CI:
0.02–6.61 and OR for OC use = 0.36;95% CI: 0.12–1.13).
Although these CIs include 1, an inverse pattern is prevalent for heavy drinkers with a greater inverse association
than among ever-
drinkers. It must also be noted that
these analyses were restricted to 169 and HNC cases and
222 controls due to the low prevalence of female heavy
drinkers.
Considering that women have considerably lower alcohol
consumption and tobacco use than men (psycho-
sociological gender-related differences), it is not surprising
that female HNC incidence is also lower. Modification
of tobacco smoking/alcohol drinking by female hormones
on HNC that were observed in our study may partly
explain the lower HNC incidence rate among women in
the general population. This would explain psycho-
sociological factors associated with fewer female HNCs.
Tobacco smoking interacts with female hormones,
increasing hepatic metabolism and estrogen catabolism
[39–41]. Increased estrogenic bioavailability augments the
risk of estrogenic side effects such as deep vein thrombosis
and female patients who are smokers are routinely cautioned against OC use. Partly due to this medical contraindication, there were too few individuals who both
used OC and smoked in our study to power an accurate
association estimate.
Although stratified analyses by BMI were hindered by
low numbers for most BMI categories, the patterns of a
J-shaped association curve for BMI with HNC are consistent with hormonally associated risk changes found in
studies for other cancers [42–44].The dose–response
decrease in HNC risk with longer HRT use duration offers
further evidence for a real relationship. Furthermore, earlier
age at pregnancy and/or birth were also favorably associated with HNC risk than never being pregnant or having
given birth. This also supports the notion that there is
a specific age range of hormone exposure that benefits
women at younger reproductive age, similar to observations found for breast cancer [6, 45].
Due to the predominant role of HPV, causing approximately 70% of oropharyngeal cancers [15], oropharyngeal
cancer must be uniquely considered in light of female
hormones. At any given time, approximately 4–7% of
individuals are expected to have oral or oropharyngeal
HPV infection [46, 47]. In half of these individuals, these
infections are cleared by the immune system [48]. It is
already been observed that men are more likely to have
an HPV infection than women and that sexual behavior
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differences could only explain 16% of this prevalence difference [46]. Women also have a higher preponderance
for autoimmune diseases such as Hashimoto thyroiditis
and multiple sclerosis than men and have a stronger
allograph rejection response than men, indicating that
certain diseases are indeed mediated by female sex hormones [49, 50]. This is supported by the observation that
sex hormones have direct effects mediated via hormone
receptors in immune cells, act through their actions on
epithelial cells and stromal fibroblast secretion of growth
factors [51], and has been observed to alter epithelial cell
proliferation in the female reproductive tract [50]. In an
epidemiological study among postmenopausal women, who
have lower physiological estrogen states, reduced immunologic fitness was observed to account for 12% of HPV
infections [52]. However, the mechanism for how the
stronger immune response conferred by female sex hormones affects oropharyngeal cancers in response to HPV
infection has not been examined, to the best of our
knowledge, and warrants further study.
As with all case–control studies, recall bias is a limitation. However, we used incident cases, which is distinct
from cases identified before data on risk factors were
collected, making recall bias less likely. Many study centers
were hospital-
based, leading to selection bias suspicion
of controls with hormone use-related conditions. However,
the majority of hospital controls were unhealthy, hospitalized due to other illnesses unrelated to hormone use,
rather than cancers. Another limitation of hospital-based
studies is lack of external validity, whereby the hospital
population differs from the general population. However,
the fact that we also found inverse associations for hormone variables with HNCs across the population-
based
studies of Iowa, Milan (2006–2009), and US multicenter
contradicts the possibility of hospital-based selection bias.
Further, the magnitudes of the inverse associations that
we have observed in our study are not dissimilar to previous prospective studies on female HNC and hormone
factors [53, 54].
Our study is strengthened by a high number of female
incident HNC cases, enabling us to evaluate the relationships between female hormones and HNC, and relationships
stratified by tobacco smoking and alcohol drinking. The
consistency of findings for high-estrogen states among both
endogenous and exogenous hormone factors supports a
true inverse association between estrogen and HNC, but
this association may be stronger at earlier age of exposure
[55]. The HRT users in our study were taking HRT for
menopausal symptoms, which consisted of both estrogen
and progesterone combined rather than unopposed estrogen.
This warrants further experimental studies to understanding
the mechanisms behind which female hormones act on
head and neck cells to prevent or reduce cancer risk.

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

In conclusion, this study supports a favorable association of female hormones with HNC. It also suggests that
the lower incidence of female HNCs may be due to a
combination of exogenous and endogenous hormone
exposure and different smoking and drinking risk
exposures.
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